IJARP Impact Factor(2018): 4.908

International Journal of Advanced Research and Publications!

Clinical Predictor For Drug Response Among Idiopathic Epilepsy Patients In Sudan

Volume 4 - Issue 2, February 2020 Edition
[Download Full Paper]

Rasha Elhassan, AbassharHussein, Abdalla Khwad, Alsadig Gasoum, Sawsan Aldeef, Mohammed Saad, Salma Elhassan, Sanna Abdulaziz, Ghada Elhassan
Epilepsy, Predictor, Factor, Pharmacoresistance, Remission.
Epilepsy is one of the common chronic neurological diseases. It spreads widely in Sudan interrupting patients, life and annoying their care givers. Antiepileptic drugs are the corner stone in the management of epilepsy. It carries a good outcome which may be enrolled by some clinical factors. These factors help in determine treatment modality. Aim of the study To identify the clinical prognostic factors of idiopathic epilepsy in Sudanese patients. Methods there were 99 patients with idiopathic epilepsy recruited from Sheikh Mohamod Kheer health centre, Omdurman, Khartoum state, Sudan; between August 2016 and February 2019. There demographic data, seizure characteristics, drugs, and concomitant conditions were recorded in dc-hoc forms. The data was analysed using excel and SPSS program to compare between good and bad outcome of patients regarding different prognostic factors, and determine the likelyhood ratio and significance by chi square test. Results over all response to treatment were good in 89%. This response was associated insignificantly with age group above 65 years, focal seizure, duration less than 5 years, or monotherapy while frequency of seizure pretreatment and good response to first regiment has significant statistical response. Conclusion There was good response to treatment especially if the seizure frequency pretreatment was low, and the patient respond well to the first treatment regimen..
[1]. P. Kwan, JW.Sander “The Natural History of Epilepsy : an Epidemiological View,” J Neurol Neurosurg Psychiatry. 75,1376-1381, 2004. doi:10.1136/jnnp.2004.045690
[2]. JWAS.Sander, “ Some Aspects of Prognosis in the Epilepsies : A Review,” Epilepsia, 34(6),1007-1016,1993.
[3]. JF. Annegers, WA .Hauser, LR .Elveback,“Remission of Seizures and Relapse in Patients with Epilepsy,” Epilepsia, 20(6),729-737,1979. doi:10.1111/j.1528-1157.1979.tb04857.x
[4]. S D .SHORVON, E H. REYNOLDS,“ Early prognosis of epilepsy, ” British Medical Journal,285, 1699-1701, 1982.
[5]. MJ .Brodie, SJE. Barry, GA.Bamagous, “ Patterns of Treatment Response in Newly Diagnosed Epilepsy, ” Neurology,78, 1548-1554,2012.
[6] . E. Beghi, Sonia Arrigoni, Arnaldo Bartocci, M. Donata Benedetti, Amedeo Bianchi, Graziella Bogliun, L. Giuseppe Bongiovanni, Daniela Buti, Giovanna Cagnin, Cesare Cardinali, Vittorio Crespi, Patrizia Ferri, Dante Galeone, Elena Gambini, Angela La Neve, Ce and PZ,“ Prognosis of Epilepsy in Newly Referred Patients : A Multicenter Prospective Study of the Effects of Monotherapy on the Long-Term Course of Epilepsy, ”Epilepsia, 33(1),45-51,1992.
[7]. S .Shinnar, JM.Pellock “ Update on the Epidemiology and Prognosis of Pediatric Epilepsy, ” Journal of Child Neurology,17,s4-17, 2002. doi:10.1177/08830738020170010201
[8]. U. Seneviratne, M .Cook, W. D’Souza“ The prognosis of idiopathic generalized epilepsy, ” Epilepsia,53(12),2079-2090, 2012. doi:10.1111/j.1528-1167.2012.03723.x
[9]. E. Beghi “ Treating epilepsy across its different stages, ” Therapeutic Advances in Neurological Disorders,3(2), 85-92,2010. doi:10.1177/1756285609351945
[10]. A. Matsumoto, S .Miyazaki, C .Hayakawa, T. Komori, M .Nakamura, A. Oshio, “ Prognostic factors for epileptic seizures in severe motor and intellectual disabilities syndrome ( SMIDS )—– A clinical and electroencephalographic study, ” Epilepsy research ,86,175-182,2009. doi:10.1016/j.eplepsyres.2009.06.005
[11] . A .Neligan, JW.Sander ,The long-term prognosis of epilepsy, chapter 36, 2011.
[12]. E. Ahmed, A Ibrahim, KM. Ali, FA.Ahmed ,“ Apparent Refractory Epilepsy ; Causes and Prevalence among Sudanese Patients at the National Center of Neurological Sciences , Khartoum 2018, ” Epilepsy Journal,5(1),1-6, 2019. doi:10.4172/2472-0895.1000133
[13]. WA. Hauser, LT. Kurland, “ The Epidemiology of Epilepsy in Rochester , Minnesota , 1935 Through 1967, ” Epilepsia ,16, 1-66,1975.
[14] . S.Q. Shafer, W. A. Hauser, J.F. Annegers, and D. W. Klass, “ EEG and Other Early Predictors of Epilepsy Remission: A Community Study, ”Epilepsia,29(5),590-600,1988.
[15]. D. G Hirtz, J. H. Ellenberg, and K. B. Nelson, “ The risk of recurrence of non-febrile seizures in children, ” Neurology, 34,637–641,1984.
[16]. WFM .Arts, OF .Brouwer, ACB .Peters, et a, “Course and prognosis of childhood epilepsy : 5-year follow-up of the Dutch study of epilepsy in childhood,” Brain, 127(March),1774-1784,2004.
[17]. W. A.Hauser, V. E .Anderson, R. B. Loewenson, and S. M. McRoberts, “Seizure Recurrence after A First Unprovoked Seizure,” New England Journal of Medicine , 307,522–5281982.
[18]. J. F. Annegers, S. B.Shirts, W. A. Hauser, and L. T. Kurland, “ Risk of Recurrence after an Initial Unprovoked Seizure,”Epilepsia , 27,43–501986.
[19]. Y. M. Hart, J. W. A. S. Sander, A. L. Johnson, and S. D. Shorvon, “ National General Practice Study of Epilepsy: Recurrence after a First Seizure ,” Lancet, 336,1271–1274,1990.
[20]. S.Blom, J. Heijbel, and P. G. Bergfors, “Incidence of Epilepsy in children: a Follow-up StudyThree Years after the First Seizure,” Epilepsia , 19,343–350,1978.
[21]. DMG .Goodridge, SD.Shorvon, “Epileptic Seizures in A Population of 6000. II: Treatment and Prognosis,”BMJ ,287,645–647,198. (n.d.).
[22]. S. Shinnar, A. T. Berg, S. L. Moshe, et al, “ Risk of Seizure Recurrence Following A First Unprovoked Seizure In Childhood:A Prospective Study,”Pediatrics , 85,1076–1085,1990.
[23]. P. R Camfield, C. S . Camfield, E. C. Smith, and J. A. Tibbles, “Newly Treated Childhood Epilepsy: A Prospective Study Of Recurrences And Side Effects,” Neurology ,35,722–725,1985.
[24]. AK. Agnihotri ,“ Treatment Outcome and Cost Of Epilepsy in A Tertiary Health Care Facilityin Northern Nigeria,”Internet J Med Updat, 10(2),25-36, 2015. doi:10.4314/ijmu.v10i2.5
[25]. S.Striano ,“The Challenges of Treating Epilepsy with 25 Antiepileptic Drugs,” Pharmacol Res, 107,211-219,2016.
[26]. D. Schmidt, W. Löscher, “Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms,”Epilepsia, 46(6),858-877,2005. doi:10.1111/j.1528-1167.2005.54904.x
[27] . A .Elmahi, M. Sawsan, AA. Alsadig, and G. Alnada,“The Effectiveness of Monotheraby in Epileptic Sudanese Patient,”Int J Res,2(05),2015;
[28]. C. Huang, L. Feng, Y. Li, et al. “Clinical Features and Prognosis of Epilepsy in The Elderly in Western China,” Seizure,38,26-31,2016. doi:10.1016/j.seizure.2016.03.011
[29] . LJ. Stephen, MJ. Brodie ,“Antiepileptic Drug Monotherapy versus Polytherapy: Pursuing Seizure Freedom and Tolerability in Adult,”Curr Opin Neurol,25(2),164-172,2012.doi:10.1097/WCO.0b013e328350ba68
[30]. JM. Finamore, MR. Sperling, T. Zhan, M .Nei, CT .Skidmore, and S.Mintzer, “Seizure Outcome after Switching Antiepileptic Drugs: A Matched, Prospective Study,” Epilepsia, 57(8),1294-1300,2016.